No abstract available.
Doxorubicin* ; Euonymus*

No abstract available.
Cardiomyopathy, Dilated* ; Doxorubicin

No abstract available.
Animals ; Doxorubicin* ; Rats*

No abstract available.
Doxorubicin* ; Etoposide* ; Stomach Neoplasms*

No abstract available.
Doxorubicin* ; Myocytes, Cardiac*

No abstract available.
Doxorubicin* ; Incidence* ; Stroke Volume*

Introduction: Doxorubicin (DOX) and paclitaxel (PTX) are both widely used anticancer drugs with a broad spectrum of antitumor activity, commonly against breast, ovarian, and lung cancers. Currently, these drugs are commercially available in liposomal formulations for their use in chemotherapy. This study generally proposed coconut oil bodies (COB) obtained from Cocos nucifera L. as an alternative carrier for DOX and PTX rather than the currently used liposome. Objectives: This study aimed to compare standard liposome and coconut oil bodies as drug carriers in terms of their microencapsulation efficiencies, lipid profiles, in vitro drug release and stability, as well as their cholesterol levels. Methods: Coconut oil bodies (COB) were isolated and purified from Cocos nucifera L. by modified sucrose gradient method followed by microencapsulation of standard drugs (doxorubicin and paclitaxel) through selfassembly and freeze-thaw method. The two standard drugs were encapsulated using COB and standard liposome. Encapsulation efficiency of both materials were determined. Lipid profiles of both encapsulating materials were analyzed by Fourier-transform infrared spectroscopy, gas chromatography-flame ionization detector, and cholesterol level determination. In vitro drug release and pH stability of both encapsulated drugs were analyzed. Results: Doxorubicin (DOX) and paclitaxel (PTX) were successfully incorporated in COB. Lauric acid was mainly abundant in COB and was able to lower cholesterol levels (5 mg/dL). COB incorporated with DOX and PTX showed stability at acidic and neutral pH. Drug release profile showed a rapid outburst within 3 hours compared to liposome encapsulated DOX and PTX. Conclusion Our study showed the encouraging potentials of using COB as wall materials that will make them attractive candidates for the formulation of pharmaceuticals for optimized drug delivery of cancer chemotherapeutics DOX and PTX
Liposomes ; Doxorubicin ; Paclitaxel

No abstract available.
Doxorubicin* ; Humans* ; Stomach Neoplasms* ; Stomach*

To investigate the chemomyectomy effect of doxorubicin on extraocular muscle, we injected 0.05ml doxorubicin into right superior rectus muscle for the experimental group and 0.05ml balanced salt solution into left superior rectus muscle for the control group of 12 rabbits. The gross and histologic examinations were done at 1, 2, 4 and 8 weeks after the injection. The results were as follows; 1. On gross examination, thickness of muscle mass at injection site was decreased with the time in the experimental group, and neither conjunctival adhesion and symblepharon nor scleral necrosis was found in both groups. 2. On microscopic examination, the degree of muscle fragmentation and necrosis was increased with the lapse of time in the experimental group. But there was no observable change with the lapse of time in the control group. These results suggested that doxorubicin was such a selective myotoxin to extraocular muscles that it could be used for nonsurgical treatment of chronic paralytic and restricted form of strabismus.
Doxorubicin* ; Muscles ; Necrosis ; Rabbits ; Strabismus

PURPOSE: To find out the myocardial protective effect of cardioxane for the myocardial damage by doxorubicin. METHODS: Using Eighteen rabbits(2.0-3.2 kg), doxorubicin(30 mg/m2) was injected intravenously once a week in group I(12 rabbits) and cardioxane(600 mg/m2) was injected at 20-30 minutes before doxorubicin administration in group II(6 rabbits). After this, we operated on the rabbits when the total cumulative dose of doxorubicin was reached at 210, 240, 270 and 300 mg/m2 and observed the degree of myocardial damage with light and electronic microscope. RESULTS: In group I, rabbits with less than 210 mg/m2 of total cumulative dose of doxorubicin, there was no definite myocardial damage but with 240 mg/m2, focal degenerative change was observed and with 300 mg/m2, severe degenerative change was detected with light microscopic examination. With electronic microscope, rabbits with less than 180 mg/m2 of total cumulative dose of doxorubicin in group I, there was no evidence of myocardial damage. In 210 mg/m2, focal degenerative change was detected. With 240 mg/m2, degenerative change was much more advanced and with 300 mg/m2, severe degenerative change was detected. In group II, no definite myocardial damage was observed even though the total cumulative dose of doxorubicin reached 300 mg/m2, but with 360 mg/m2, there was a focal area where myocardial fibers were somewhat decreased, but it's difficult to say whether these decrement were due to adriamycin in the electronic microscopic examination. CONCLUSION: Cardioxane have a good protective effect for the doxorubicin induced cardiomyopathy and it will be used safely in pediatric cancer patients.
Cardiomyopathies ; Dexrazoxane* ; Doxorubicin* ; Humans ; Rabbits